John Haurum, formerly chief executive of F-star Biotechnology Ltd, has been appointed to the board of Storm Therapeutics Ltd as an independent non-executive director. Storm is focused on the discovery of small molecule therapies that modulate RNA epigenetics. Dr Haurum has more than 20 years of experience in the international biotech industry. Prior to F-star, he was vice president of research at ImClone Systems Inc and before that, chief scientific officer and co-founder of the antibody company Symphogen A/S in Denmark. He has a medical degree and Master of Science in immunology from Aarhus University in Denmark and a DPhil in immunology from the University of Oxford in the UK.
Storm Therapeutics announced the appointment on 27 June 2019.
Copyright 2019 Evernow Publishing Ltd.